Department of Urology, Médecine Sorbonne Université, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Department of Urology, University Hospital CHUV, Lausanne, Switzerland.
Department of Urology, Médecine Sorbonne Université, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Eur Urol. 2021 Jun;79(6):858-865. doi: 10.1016/j.eururo.2020.08.005. Epub 2020 Oct 2.
Augmentation cystoplasty as a third-line therapy for neurogenic detrusor overactivity performed by an open approach has long been studied. Few laparoscopic and robot-assisted series have been reported.
To evaluate the feasibility, safety, and functional outcomes of completely intracorporeal robot-assisted supratrigonal cystectomy and augmentation cystoplasty (RASCAC) in patients with refractory neurogenic detrusor overactivity.
DESIGN, SETTING, AND PARTICIPANTS: We identified all patients undergoing RASCAC, as treatment for refractory neurogenic detrusor overactivity, from August 2016 to April 2018.
RASCAC was performed in all cases using a standardized technique with the da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA, USA) in a four-arm configuration.
Perioperative data, and functional and urodynamic results at 1-yr follow-up were assessed. Statistical analysis was performed using Stata version 15.1.
Ten patients were identified. No conversion to open surgery was needed. The median operative time was 250 (interquartile range 210-268) min, the median estimated blood loss was 75 (50-255) ml, and the median hospitalization time was 12 (10.5-13) d. The 30-d major complication rate was 10%. Two patients presented a late urinary fistula; in one of the cases, surgical revision was needed. In both cases, low compliance to intermittent self-catheterization was identified. At 1-yr follow-up, functional and urodynamic outcomes were excellent.
Robot-assisted augmentation cystoplasty has been shown to be safe and feasible, with a reasonable operative time and low complication rate in experienced hands. A higher number of patients and longer follow-up are, however, warranted to draw definitive conclusions.
In this report, we look at the outcomes of robot-assisted supratrigonal cystectomy and augmentation cystoplasty in neurourological patients. Perioperative, functional, and urodynamic results are promising. Further studies with a longer follow-up are needed to confirm these findings.
通过开放式手术进行的第三线治疗神经源性逼尿肌过度活动的膀胱扩大术已有长期研究。很少有腹腔镜和机器人辅助系列报道。
评估完全经体腔机器人辅助上三角胱切除术和膀胱扩大术(RASCAC)在难治性神经源性逼尿肌过度活动患者中的可行性、安全性和功能结果。
设计、设置和参与者:我们确定了 2016 年 8 月至 2018 年 4 月期间所有接受 RASCAC 治疗难治性神经源性逼尿肌过度活动的患者。
所有病例均采用达芬奇手术系统(Intuitive Surgical,加利福尼亚州森尼韦尔)四臂配置的标准化技术进行 RASCAC。
评估围手术期数据以及 1 年随访时的功能和尿动力学结果。使用 Stata 版本 15.1 进行统计分析。
确定了 10 例患者。无需转为开放性手术。中位手术时间为 250(四分位间距 210-268)min,中位估计出血量为 75(50-255)ml,中位住院时间为 12(10.5-13)d。30 天主要并发症率为 10%。2 例患者出现迟发性尿瘘;其中 1 例需要手术修正。在这两种情况下,都发现间歇性自我导尿的顺应性较低。1 年随访时,功能和尿动力学结果均良好。
在经验丰富的医生手中,机器人辅助膀胱扩大术已被证明是安全可行的,手术时间合理,并发症发生率低。然而,需要更多的患者和更长的随访时间来得出明确的结论。
在本报告中,我们研究了机器人辅助上三角胱切除术和膀胱扩大术在神经泌尿学患者中的应用。围手术期、功能和尿动力学结果有希望。需要进一步的研究和更长时间的随访来证实这些发现。